| |
BMS Co-Payment Assistance Program
|
| |
| |
Bristol-Myers Squibb will begin offering a co-payment assistance program within the first half of this year for new and existing REYATAZ (atazanvir) and SUSTIVA (efavirenz) patients with commercial insurance. We recognize that especially in this economic environment, out-of -pocket costs for HIV medicines may be prohibitive even for patients who have prescription drug benefits. This program reflects our ongoing commitment to ensuring patients who need our medicines are able to access them. As you know, Bristol-Myers Squibb already has initiatives in place to support access to medicines for uninsured and underinsured patients living with HIV. For example, BMS participates in the pharmaceutical industry's Together RX Program. In addition, BMS provides our medicines free of charge for those who qualify through our Patient Assistance Program. We are working quickly to finalize the structure of the co-payment assistance program and will provide more detailed information to you in the near future. In the meantime, we would like to thank the many individuals and groups within the community who have lent their insights to the continued development of Bristol-Myers Squibb's access programs. We appreciate your collaboration in our efforts to continue to meet the needs of the community.
|
|
| |
| |
|
|
|
